medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-9-6-10medsovet-1374Research ArticleКАРДИОЛОГИЯCARDIOLOGYАпиксабан – от рекомендаций к повседневной практикеAPIXABAN – FROM RECOMMENDATIONS TO EVERYDAY PRACTICEЕЛИСЕЕВАЛ. Н.ELISEEVAL. N.

д.м.н., профессор

MD, Prof.

БЛЕДНОВАА. Ю.BLEDNOVAA. Y.

к.м.н.

PhD

ДЕНИСОВАН. Н.DENISOVAN. N.ШУХАРДИНАЕ. Л.SHUKHARDINAE. L.Кубанский государственный медицинский университет Минздрава России, КраснодарРоссияKuban State Medical University of the Ministry of Health of Russia, KrasnodarRussian Federation«ООО Сити клиник» поликлиника, КраснодарРоссияCity Clinic LLC polyclinic, KrasnodarRussian Federation20163012201609610Copyright © ЕЛИСЕЕВА Л.Н., БЛЕДНОВА А.Ю., ДЕНИСОВА Н.Н., ШУХАРДИНА Е.Л., 20162016ЕЛИСЕЕВА Л.Н., БЛЕДНОВА А.Ю., ДЕНИСОВА Н.Н., ШУХАРДИНА Е.Л.ELISEEVA L.N., BLEDNOVA A.Y., DENISOVA N.N., SHUKHARDINA E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1374

В статье представлен анализ отдельных клинических ситуаций у пациентов с наличием фибрилляции предсердий в аспекте обоснования выбора антикоагулянтной терапии с использованием апиксабана в свете последних (2015 г.) рекомендаций Европейской ассоциации аритмологов (European Heart Rhythm Association). Авторы проводят анализ необходимости и возможности использования орального антикоагулянта апиксабана с целью профилактики инсульта у пациентов с неклапанной фибрилляцией предсердий. В целом новые оральные антикоагулянты превосходят терапию варфарином в способности снижать риск тромбоэмболических осложнений и особенно ятрогенного геморрагического инсульта у больных с неклапанной фибрилляцией предсердий. В статье обоснованы ситуации преимущественного выбора апиксабана в конкретных клинических ситуациях.

The articles deals with the analysis of clinical situations in patients with atrial fibrillations in the aspect of choice of the anticoagulant therapy with apixaban use in relation with the recent (2015) recommendations of the European Heart Rhythm Association. The authors conduct analysis of necessity and possibility to use the oral anticoagulant apixaban to prevent stroke in patients with non-valvular atrial fibrillation. On the whole, new oral anticoagulants exceed the warfarin therapy in he capability to reduce the risk of thrombolytic complications and iatrogenic hemorrhagic stroke in patients with non-valvular atrial fibrillations. The article demonstrates justification of situations of predominant apixaban selection in certain clinical settings.

фибрилляция предсердийинсультварфаринновые оральные антикоагулянтыапиксабанatrial fibrillationstrokewarfarinnew oral anticoagulantsapixabanReferencesnewsruss.ru/doc/index.php.newsruss.ru/doc/index.php.www.rosminzdrav.ru/news/2014/10/20/2071.www.rosminzdrav.ru/news/2014/10/20/2071.Feigin LV, Lawes CMM, Bennett DA, et al., Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol, 2009,Feigin LV, Lawes CMM, Bennett DA, et al., Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol, 2009,: 355-69.: 355-69.Скворцова В.И., Губский Л.В., Стаховская Л.В. и др. Ишемический инсульт. В кн.: Неврология. Национальное руководство. Под ред. Е.И.Гусева, А.И.Коновалова, В.И.Скворцовой. М. ГЭОТАР-МЕДИА; 2009, С.592-613.[Skvortsova VI, Gubskii LV, Stakhovskaya LV, et al. Ischemic stroke. In: Nevrologiya, national`noe rukovodstvo [Neurology. National Guide]. Guseva EI, Konovalova AI, Skvortsovji VI, editors. Moscow: GEOTAR-MEDIA, 2009: 592-615.Скворцова В.И., Губский Л.В., Стаховская Л.В. и др. Ишемический инсульт. В кн.: Неврология. Национальное руководство. Под ред. Е.И.Гусева, А.И.Коновалова, В.И.Скворцовой. М. ГЭОТАР-МЕДИА; 2009, С.592-613.[Skvortsova VI, Gubskii LV, Stakhovskaya LV, et al. Ischemic stroke. In: Nevrologiya, national`noe rukovodstvo [Neurology. National Guide]. Guseva EI, Konovalova AI, Skvortsovji VI, editors. Moscow: GEOTAR-MEDIA, 2009: 592-615.Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke, 2006, 37: 577-617.Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke, 2006, 37: 577-617.Chugh SS, Havmoeller R, Narayanan K et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation, 2014, 129: 837-847.Chugh SS, Havmoeller R, Narayanan K et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation, 2014, 129: 837-847.Reiffel JA. Atrial fibrillation and stroke: epidemiology. Am J Med., 2014, 127: e15-е16.Reiffel JA. Atrial fibrillation and stroke: epidemiology. Am J Med., 2014, 127: e15-е16.Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol., 2014, 6: 213-220.Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol., 2014, 6: 213-220.Рекомендации 2015 European Heart Rhythm Association Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace Advance Access published August 31, 2015.Рекомендации 2015 European Heart Rhythm Association Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace Advance Access published August 31, 2015.Go AS, Hylek EM, Philips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001, 285: 2370-5.Go AS, Hylek EM, Philips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001, 285: 2370-5.Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009, 104: 1534-9.Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009, 104: 1534-9.The ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet, 2006, 367: 1665- 1673.The ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet, 2006, 367: 1665- 1673.AVERROES Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med., 2011, 364: 806–17.AVERROES Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med., 2011, 364: 806–17.Camm AJ, Lip GY, De Caterina R. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart Journal, 2012, 33(21): 2719-47.Camm AJ, Lip GY, De Caterina R. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart Journal, 2012, 33(21): 2719-47.Baker W, Cios D, Sander S, Coleman CI. Metaanalysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm., 2009, 15(3): 244-52.Baker W, Cios D, Sander S, Coleman CI. Metaanalysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm., 2009, 15(3): 244-52.Cucchiara BL, Kasner SE. Apixaban in atrial fibrillation: from bleeding cows to 21st century medicinal chemistry. Stroke, 2011, 42: 2376-8.Cucchiara BL, Kasner SE. Apixaban in atrial fibrillation: from bleeding cows to 21st century medicinal chemistry. Stroke, 2011, 42: 2376-8.Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Москва, 2012. 112 c. [Diagnostics and treatment of fibrillation of auricles. Recommendations of PKO, BHOA and ACCX. Moscow; 2012. 112 p]. Moscow; 2012. 112 p.];Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Москва, 2012. 112 c. [Diagnostics and treatment of fibrillation of auricles. Recommendations of PKO, BHOA and ACCX. Moscow; 2012. 112 p]. Moscow; 2012. 112 p.];January CT, Wann LS, Alpert JS et al. Guideline for the Management of Patients with Atrial Fibrillation: Executive Summary. J Am Coll Cardiol., 2014, 63. Available from: www.cardiosource. org.January CT, Wann LS, Alpert JS et al. Guideline for the Management of Patients with Atrial Fibrillation: Executive Summary. J Am Coll Cardiol., 2014, 63. Available from: www.cardiosource. org.You JJ, Singer DE, Howard PA, et al. Anti thrombotic therapy for atrial fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest., 2012, 141(2 Suppl): e531S- 75S.You JJ, Singer DE, Howard PA, et al. Anti thrombotic therapy for atrial fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest., 2012, 141(2 Suppl): e531S- 75S.Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2012, 43: 3442-53.Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2012, 43: 3442-53.Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 2014, 45: 2160-236.Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 2014, 45: 2160-236.Heidbuchel H, Verhamme P, Alings M, et al.European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15(5): 625-51.Heidbuchel H, Verhamme P, Alings M, et al.European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15(5): 625-51.Culebras A, Messe SR, Chaturvedi S, et al. Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014, 82: 716-24.Culebras A, Messe SR, Chaturvedi S, et al. Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014, 82: 716-24.Granger ChB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med., 2011, 365: 981-92.Granger ChB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med., 2011, 365: 981-92.Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood, 2010, 115: 15-20.Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood, 2010, 115: 15-20.Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med., 2011, 365: 981-992.Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med., 2011, 365: 981-992.Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts. Circulation, 2013, 127: 224-32.Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts. Circulation, 2013, 127: 224-32.Camm AJ, Savelieva I. “R” for “renal” and for “risk”: refining risk stratification a29. Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB. Renal function and nonvitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol, 2015, 104: 418-29.Camm AJ, Savelieva I. “R” for “renal” and for “risk”: refining risk stratification a29. Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB. Renal function and nonvitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol, 2015, 104: 418-29.

The authors declare that there are no conflicts of interest present.